II. Mechanism
- Transdermal patches release Hormones at constant rate
III. Preparations
- Ortho Evra
- Ethinyl Estradiol 20 mcg/day
- Norelgestromin 150 mcg/day
- Xulane
- Ethinyl Estradiol 35 mcg/day
- Norelgestromin 150 mcg/day
- Twirla
- Ethinyl Estradiol 30 mcg/day
- Levonorgestrel 120 mcg/day
IV. Technique: 4 week cycles
V. Efficacy
- Ortho Evra
- Failure rate: 0.88 pregnancies per 100 woman years
- Lower efficacy if weight >198 pounds (90 kg)
- Twirla
- Lower efficacy rate if BMI >30
VI. Adverse effects
- Overall patch has similar adverse effects to OCP
- Transdermal specific adverse effects
- Contact Dermatitis reaction to patch
- Detachment rate: 2.8% of patches partially detach (Ortho Evra)
- Increased adverse effects in first two months
-
Thromboembolism risk may be as high as twice the risk of Oral Contraceptives
- Likely related to the higher Estrogen concentrations in the patch compared with Oral Contraceptives
- Cole (2007) Obstet Gynecol 109(2 Pt 1):339-46 [PubMed]
VII. Benefits
- Higher compliance rate than with Oral Contraceptives
VIII. References
- (2020) Presc Lett 27(12): 70
- Herndon (2004) Am Fam Physician 69(4):853-60 [PubMed]
Images: Related links to external sites (from Bing)
Related Studies
xulane (on 3/22/2023 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
XULANE 150-35 MCG/DAY PATCH | Generic | $39.46 each |
twirla (on 7/15/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
TWIRLA 120-30 MCG/DAY PATCH | $60.61 each |